• Explore /
  • Poster
  • / Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.

Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.

Abstract Poster

Authors

null

Nelson Spector

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Nelson Spector , Nelma Cristina D. Clementino , Pedro Enrique Dorlhiac-Llacer , Brian Leber , Timothy P. Hughes , Francisco Cervantes , Anthony P. Schwarer , Donna L. Forrest , Suzanne Kamel-Reid , Israel Bendit , Sandip Acharya , LaTonya Collins , Darshan Dalal , Jeffrey H. Lipton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

CAMN107A2405

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7025)

DOI

10.1200/jco.2014.32.15_suppl.7025

Abstract #

7025

Poster Bd #

17

Abstract Disclosures

Similar Posters

First Author: Nelson Spector

First Author: Richard A. Larson

First Author: Benjamin J. Solomon

First Author: James E. Signorovitch